EP
RNA icon

Essential Partners’s Atrium Therapeutics RNA Stock Holding History

Essential Partners’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$654 Sell
79
-209
-73% -$2.47K ﹤0.01% 2317
2026
Q2 		$3.87K Buy
+288
New +$3.76K ﹤0.01% 1659

Other funds holding RNA

TC
Trium Capital London, United Kingdom $79.4M AUM 36.67% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FIA
FNY Investment Advisers New York $402M AUM 85.34% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners's RNA Position: Q3 2026 in Review

Essential Partners reduced its Atrium Therapeutics (RNA) stake by 73% in Q3 2026, selling an estimated $2.47K and leaving 79 shares worth $654. The position accounts for ﹤0.01% of the portfolio, ranked #2317.

Essential Partners first reported a position in RNA in Q2 2026 and has held it in 2 quarters since. The position peaked at $3.87K in Q2 2026. 9 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • Essential Partners held 79 shares of Atrium Therapeutics worth $654 as of Q3 2026.
  • Essential Partners sold 209 Atrium Therapeutics shares in Q3 2026, an estimated $2.47K.
  • Atrium Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2317 holding.
  • Essential Partners first reported a position in Atrium Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Essential Partners's Atrium Therapeutics position peaked at $3.87K in Q2 2026.
  • 9 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.